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Background:  Progression  to a chronic  state  after  an  initial,  mostly  asymptomatic,  acute
phase is  the normal  fate  of  Toxoplasma  infection  in  immunocompetent  hosts.  The  inter-
conversion  between  tachyzoite  and  bradyzoite  life  stages  is a key  to  Toxoplasma  survival
and pathogenesis.  Chronic  toxoplasmosis  is resistant  to all commercially  available  medi-
cations. Reactivation  of  chronic  stage  has  serious  complications  on  immunocompromised
hosts  including  encephalitis  and  death.  Cyclic AMP,  TNF-  and Th1  immune  response  have
pivotal  roles  in establishing  chronic  disease.  Rolipram,  a PDE4  inhibitor,  has regulatory
roles  on  these  factors.  This  is  the  ﬁrst study  to  investigate  a possible  modulatory  effect
of  rolipram  on  Toxoplasma  infection  in  an  experimental  murine  model.  The  ability,  of  this
novel  regimen  to  prevent  or reverse  Toxoplasma-induced  pathology  was  evaluated.
Materials and  methods:  Toxoplasma-infected  mice  received  rolipram  (10  mg/kg)  daily  for
three weeks.  Life  expectancy,  serum  ALT  and  histopathology  of liver and brain  were  the
parameters  used  to evaluate  therapeutic  and/or  toxic  impact  of rolipram  in  comparison
with  infection  and  healthy  control  groups  of mice.
Results: Toxoplasma-induced  pathology  was  never  completely  cleared  by  rolipram.  How-
ever, a signiﬁcant  impact  in  aborting  chronic  state  and  in  mitigating  pathology  was  detected.
The drug  almost  normalized  Toxoplasma-induced  high  ALT  levels  reversing  the  hepatotoxic
effect  of the  parasite.
Conclusion:  This  study  is  the  ﬁrst to demonstrate  relative  merits  of rolipram  therapy  to
toxoplasmosis  with  illustration  of  its  efﬁcacy  and  toxicity.  It reports  a novel  approach  with
potential future  beneﬁts  using  PDE  inhibitors  to  abort  resistant  latent  phases  of biologically
related  infectious  agents.
© 2014  Saudi  Society  of  Microscopes.  Published  by Elsevier  Ltd.  All  rights  reserved.∗ Corresponding  author at: Department of Medical Microbiology and
Parasitology, Faculty of Medicine, King Abdulaziz University, P.O. Box
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Toxoplasma gondii is an obligatory intracellular pro-
tozoan parasite with a world-wide distribution. An
approximate 25–30% of the world’s human population is
infected  by Toxoplasma. The infection is mostly asymp-
tomatic in immunocompetent persons; however, it leads
ghts reserved.
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was  performed on blood samples of day 14; 2 weeks after
infection (1 week after onset of treatment). Blood sam-
ples  were collected from individual mice from the tail vein
and  allowed to clot at room temperature. The serum wasM.A. Aﬁﬁ et al. / Journal of Micros
o a severe and life-threatening disease in congenitally
nfected infants and individuals with suppressed immu-
ity  [1]. After acute infection, T. gondii establishes a latent
hase  of the disease. Reactivation of latent infection,
n immunocompromised persons, causes dissemination
f parasites and development of serious complications
ncluding encephalitis [2].
Microbial persistence and latency are conserved strate-
ies  that many pathogens use to circumvent host resistance
echanisms. The ability of Toxoplasma to establish a
hronic  phase, through conversion into bradyzoite, is
n  evolutionary trade-off that reduces virulence while
ncreasing transmission [3]. Tumor necrosis factor- (TNF-
)  and cyclic adenosine monophosphate (cAMP) are among
he  main factors in favor of latency of Toxoplasma infection
hrough enhancing tachyzoite differentiation to bradyzoite
4].  TNF-, produced by activated macrophages in response
o  T. gondii infection, synergizes with interferon-gamma
IFN-) [5] and interleukin-12 (IL)-12 [6], to orchestrate
he transition from the pharmacologically vulnerable acute
tate  to the resistant and long-lasting chronic toxoplasmo-
is [7,8].
With no vaccine available to prevent or abort Toxo-
lasma infection, drugs remain the primary strategy for
he  treatment of human toxoplasmosis. While several
rugs are available which control acute toxoplasmosis, no
reatment  exists which can eliminate the cysts and treat
hronic infection. It seems impossible to pharmacologically
ttack a dormant encysted brain parasite that keeps a low
etabolic proﬁle [9]. The available medications exhibit also
any  side effects that make them poorly tolerable [10].
herefore, characterization of new targets for drugs could
ead  to a novel array of medications capable of better treat-
ent  of toxoplasmosis.
Phosphodiesterase-4 (PDE4) inhibitors, including
olipram, exhibit two main actions that, in theory, could
nterfere with the transition of Toxoplasma infection
o a chronic phase. PDE4 inhibitors induce a positive
odulation of the intracellular cAMP response lead-
ng  to intracellular cAMP elevation [11]. Cyclic AMP
ignaling pathways within the parasite is likely to be
ritical in the conversion of T. gondii tachyzoites to
radyzoites. Agents predicted to cause sustained eleva-
ion  of cAMP were found to be inhibitory to T. gondii
achyzoite–bradyzoite conversion and negatively inﬂu-
nce  tachyzoite maturation [4]. PDE4 inhibitors are
lso  known to induce a potent shift toward a T-helper2
Th2) type immune response [12]. This, in turn, leads
o  a reduction in the activity of pro-inﬂammatory Th1
ytokines with particular inhibition of TNF- [13,14]; a
ain  factor in parasitic conversion to the bradyzoite stage
8,9].
A  drug capable of preventing the establishment of
atent infection, without exacerbation of the acute phase,
ould  revolutionize current T. gondii therapy by pre-
enting the dangerous consequences of latent phase
eactivation in immunosuppressed patients. Pharmaco-
ogic immunomodulators, which may  inhibit several
athways in the immune system by multiple mechanisms,
ave been rarely tried as antiparasitic agents. Phos-
hodiestrase inhibitors, including rolipram, have neverd Ultrastructure 2 (2014) 94–99 95
investigated as possible candidates for the treatment of
toxoplasmosis.
The  current study is the ﬁrst to investigate a possible
modulatory effect of rolipram, a PDE4 inhibitor, on Toxo-
plasma  infection in an experimental murine model. The
ability  of this novel therapeutic regimen to prevent or
reverse  toxoplasmic pathology was evaluated.
2. Materials and methods
2.1.  Animals
Six  to eight weeks old female Swiss albino mice,
weighting 25–30 g were kept under standard laboratory
conditions. Mice were split into three experimental groups
(10  mice each) where the ﬁrst group (GI) were challenged
with T. gondii (KSU strain). The second group (GII) were
challenged with parasites, as in G1 but received rolipram,
while the third group (GIII) received rolipram (same regi-
men  as in GII) without a parasitic challenge.
2.2. Parasites and infection
The  low pathogenic KSU strain of T. gondii was  a gen-
erous gift from Ain-shams Diagnostic and Research Unit,
Cairo,  Egypt where it is regularly maintained. Mice groups
I  & II were infected by intraperitoneal (i.p.) injection with
20  tissue cysts in a total volume of 0.1 ml  sterile emulsion
of  a brain of a Swiss albino mouse infected two  months
earlier.
2.3. Drug preparation and application
Ten milligrams of rolipram (Sigma, USA), were dis-
solved in 0.2 ml  of dimethyl sulfoxide (Sigma, USA) which
was  then diluted to a total volume of 10 ml  with distilled
water to reach a ﬁnal concentration of 1.0 mg/ml. The solu-
tion  was subjected to repeated cycles of heating (30 s at
60 ◦C) and cooling (room temperature for 2 min) in order
to  achieve complete solubility of the drug in water [15].
The  solution was then frozen into aliquots at 20 ◦C until
used. Rolipram at a dose of 10 mg/kg/day was  adminis-
tered orally once daily [16] from day 7 post-infection and
for  three weeks to each mouse of GII & GIII.
2.4. Blood sampling and assay for serum alanine
aminotransferase (ALT)
Alanine  aminotransferase (ALT) measurement (U/L),collected by centrifugation and stored at −70 ◦C until the
day  of assay. Plasma ALT levels were determined with a
standard  photometric assay using a commercial kit (Sigma,
St.  Louis, MO).
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Table  1
Levels of alanine amino-transferase (ALT) (IU/L) in different experimental groups and the relation to hepatotoxicity.
Rolipram (10 mg/kg) T. gondii challenge (20 tissue cysts/0.1 ml)  Alanine amino-transferase (ALT) (IU/L) Hepatotoxicity
Nil Nil 14.5 ± 2.6 –
Nil (+) 35.7 ± 4.3* Grade I
(+)  Nil 14.8 ± 2.2 Nil
**
ated inf(+) (+) 
* Signiﬁcant difference (P < 0.05) from normal control and rolipram-tre
** Signiﬁcant difference (P < 0.05) from non-treated infected mice.
2.5. Hepatotoxicity grading
We  applied the criteria based on the World Health Orga-
nization Adverse Reaction Terminology (WHO-ART) [17],
originally  developed for human subjects, to assess the like-
lihood  of hepatotoxicity induced by either drug or parasite.
The  application of this grading system on experimental
murine models was done before [18]. Brieﬂy, ALT serum
levels  of 51–125 IU/L (or 1.25–2.5× the normal) indicate
Grade 1 hepatotoxicity; grade 2 is indicated at serum lev-
els  of 126–250 IU/L (or 2.6–5.0× the normal); ALT levels
at  251–500 IU/L (or 5.1–10.0× the normal) indicate grade
3;  while grade 4 should be considered at ALT levels of
>500  IU/L, or >10.0 times the normal [17].
2.6.  Histopathological analysis
Livers, of two mice from each group sacriﬁced at day-14
(2  weeks after infection and 1 week after onset of treat-
ment), were processed to examine T. gondii pathology at
this  stage of infection. Brains from mice were taken at
the  end of the experiment (day-50) to examine for brain
pathology. Organ selection for histopathology, deferred to
the  known nature of Toxoplasma infection in a mouse host.
Liver  and brain are naturally among the most targeted
organs during T. gondii infection with an extent of pathol-
ogy  that is relatively more severe [19]. The sampling time;
two-weeks post-infection for liver and 50 days for brain
conform to the predicted kinetics of infection in such a
host  [20]. All specimens were immediately ﬁxed in 10%
formaldehyde. Samples were then embedded in parafﬁn
wax,  cut into 6-m sections, and stained with hematoxylin
and eosin prior to microscopic examination.
2.7. Statistical analysis
All  data were expressed as mean ± SD. The data obtained
from various groups were analyzed using Student’s t-test.
The  value of P < 0.05 was considered as statistically signif-
icant.  Data entry and analysis were processed using SPSS
software version 18.
3.  Results
3.1. Liver transaminases
Challenge of mice with 20 cysts of T. gondii (KSU strain)
was able to induce a grade-1 hepatotoxicity with a highly
signiﬁcant increase of ALT activity (>2-times the normal
level). No signiﬁcant hepatotoxic effect of rolipram was
detected in this study; instead, it was partially protective18.1 ± 3.8 Nil
ected mice.
against the hepato-toxic effect of Toxoplasma infection.
Rolipram exerts a signiﬁcant lowering effect on ALT lev-
els,  in Toxoplasma-infected mice compared to infected but
non-treated mice. Rolipram has managed to bring the ALT
levels  to values slightly and non-signiﬁcantly higher than
normal  (Table 1).
3.2.  Liver and brain pathology
The  results of the current study showed that the pathol-
ogy inﬂicted by T. gondii infection was never cleared
by rolipram-modulated immune response, nevertheless,
Toxoplasma-induced steatosis and inﬂammation were dra-
matically  opposed, by the drug, in liver and brain (Fig. 1).
Toxoplasma-infected mice group showed an intense
liver pathology with a localized but heavy peri-sinusoidal
inﬁltration with large number of mononuclear cells;
macrophages and lymphocytes. Marked fatty changes of
hepatocytes were also present (Fig. 1A). A mitigated form of
liver  pathology was encountered in rolipram-treated mice
compared  to that in the non-treated group. Hepatocytes
showed an almost normal appearance with mild but dif-
fuse  mononuclear cell inﬁltration. Few macrophages and
lymphocytes were also seen inside the sinusoid (Fig. 1B).
The  brain tissue of non-treated infected mice showed
moderate inﬂammation with dilated and congested blood
vessels  and a trail of mononuclear inﬂammatory cells
inﬁltration (Fig. 1C). While, the liver pathology, in rolipram-
treated infected mice, was mitigated, the brain tissue, of
this  group, was almost normal. Brain pathology showed
few  scattered mononuclear cell inﬁltration (Fig. 1D).
3.3.  Animals life expectancy
In  spite of varying degrees of pathology in multiple
organs listed above, mice from all experimental groups
remain living until sacriﬁced at day-50 but with vary-
ing  degrees of morbidity. Non-treated infected mice were
the  most morbid followed by those of rolipram-treated
infected mice while those belonging to the rolipram-
treated, non-infected group were apparently healthy and
active  till the end of the experiment.
4. Discussion
Prevention of the establishment of the treatment-
resistant [21] chronic phase of toxoplasmosis, might
avert the clinically serious consequences of reactivation
in immunocompromised patients. However, the most
widely used chemotherapeutics to avoid severe clinical dis-
ease  through suppressing Toxoplasma replication, such as
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Fig. 1. Rolipram modulation of T. gondii pathologic impact. (A) Liver of a Toxoplasma-infected mouse showing a heavy peri-sinusoidal mononuclear cell
inﬁltration  with marked fatty changes of hepatocytes (100×). (B) Liver of a Toxoplasma-infected, rolipram-treated mouse with mild mononuclear cell
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inﬁltration  with hepatocytes retain an almost normal appearance (100×
ononuclear  inﬂammatory cells. Dilated and congested blood vessels are
ild  inﬂammation with few scattered mononuclear cells (100×).
yrimethamine-sulfadiazine and atovaquone, were found
o  promote latency of infection and stage conversion to
radyzoite [22,23].
We  selected a single pharmacologic agent; rolipram,
hat is able to attack multiple pathways involved in the
rogression to chronic toxoplasmosis. Rolipram has mod-
latory  effects on both cAMP signaling and Th1 immune
esponse which are crucial factors of such progression.
AMP is a universal messenger, for nearly all eukaryotes
24], including many parasites [25] to adapt to envi-
onmental or host changes. Cyclic nucleotide signaling
athways have been implicated in stress-induced differ-
ntiation and immune evasion in parasites other than T.
ondii  like Plasmodium [26,27], and Trypanosoma cruzi [28].
he  Th1 immune response may  also trigger the transition
o  the bradyzoite stage [29], working as a stabilizer of the
atent  form of toxoplasmosis in immunocompetent hosts
30].  TNF- secretion, together with low concentrations of
FN-,  synergistically induce such type of transition [31].
This  study extends a series of recent and signiﬁcant
eports [32–36] that have examined novel approaches to
reat  Toxoplasma infection especially in its drug-resistant
hronic phase [37]. A unique aspect of our study is
he  novel approach of pharmacologic prevention rather
han  pharmacologic treatment of chronic toxoplasmosis.
onsidering the unfeasible eradication of the parasitic
mpenetrable cysts, that are also impervious to the immune
esponse [9], we decided to shift the center of attention to
ather  abort the formation of these cysts.
We have shown for the ﬁrst time that treatment with
olipram successfully prevented biochemical and histolog-
cal  signs of Toxoplasma-induced hepatitis in mice as wellrain of an infected mouse showing moderate inﬁltration with a trail of
n (100×). (D) Brain of an infected mouse treated with rolipram showing
as  the expected brain pathology of latent toxoplasmosis.
The histopathology ﬁndings were the most demonstra-
tive evidence of the protective effect of rolipram. This
novel anti-Toxoplasma therapeutic approach was  able to
signiﬁcantly reduce the pathology in both liver and brain
to  a trivial degree. Rolipram, is reported to have tissue-
protective and anti-inﬂammatory effects through marked
downregulation of pro-inﬂammatory cytokines especially
TNF- [38]. This relatively moderate protective effect was
not  undermined by any toxic effect. The rolipram-induced
histopathological pattern showed no deleterious effects
of  concern. The issue of safety of rolipram was  more
evident in ALT levels. Rolipram-triggered ALT elevations
were insigniﬁcant, moreover, the drug was able to reverse
Toxoplasma-induced toxic effects.
However, with any pharmacological study, there could
be  points of concern that might abrogate the beneﬁcial
effects. In this study, the main concern, of using rolipram
to  abort chronic toxoplasmosis, was the possibility of exac-
erbation  of the acute stage driving mice to succumb to a
lethal  outcome. While play a pathogenic role in the devel-
opment of Toxoplasma-induced inﬂammation, TNF- and
other  Th1 cytokines, mainly IFN-, have a protective effect
preventing the development of a lethal acute toxoplasmo-
sis in susceptible hosts such as mice. The immunodulatory
actions, of rolipram, up-regulating cAMP and inhibiting
TNF- secretion were expected to result in an exception-
ally morbid acute stage; a possibility that did not show in
our  results. This ﬁnding, together with a partial rather than
complete  protective effect of rolipram, could be explained
on  the basis of a weaker suppressant effect of rolipram
on IFN- secretion compared to that on TNF- [39].
scopy an
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[98 M.A. Aﬁﬁ et al. / Journal of Micro
IFN- while synergize with TNF- to mediate resistance
to acute Toxoplasma infection and transition to the chronic
state,  it could mediate such action independent from other
cytokines  [9]. We  suggest that incompletely inhibited IFN-
,  prevented acute phase exacerbation but was still able to
mediate  partial progression to a mitigated latent state.
The  demonstrated modulating effect of rolipram, on T.
gondii  infection, could be partly inﬂuenced by the Toxo-
plasma strain used in our study. The used KSU strain is
a  cyst-forming one that is particularly suitable for cAMP
manipulation by PDE4 inhibitors. Interestingly, elevation
of  the parasite cAMP level, in response to PDE4 inhibitors,
was critically associated with the ability of T. gondii to dif-
ferentiate to the bradyzoite stage. This ﬁnding was  only
observed in a related cyst-forming strain (PLK). The same
ﬁnding  was not recovered on using a virulent strain (RH)
that  have a poor differentiating capacity to bradyzoites [4].
The  possibility of discrepant modulating effects of PDE4
inhibitors on cAMP in relation to Toxoplasma strains raises a
concern  of possible heterogeneous responses to treatment
according to the strain of the infecting parasite.
5. Conclusion
In summary, this study has shown the impact of
rolipram on tissue responses, of a murine model, to in vivo
T.  gondii infection. It has shed the light on the relative mer-
its  of rolipram therapy to toxoplasmosis with illustration
of  its efﬁcacy and toxicity. Thus, immune responses and
molecular host–Toxoplasma interactions should be consid-
ered  and further studied to understand the precise role of
PDE4  inhibitors in modulating the course of infection. In
conclusion, the study reports a novel and effective thera-
peutic approach with potential future beneﬁts using PDE
inhibitors to abort resistant latent phases of biologically
related infectious agents.
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